Analyzing Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) and Trinity Biotech (NASDAQ:TRIB)

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) and Trinity Biotech (NASDAQ:TRIB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Senseonics Holdings, Inc. Common Stock and Trinity Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senseonics Holdings, Inc. Common Stock	1	1	4	0	2.50
Trinity Biotech	1	0	0	0	1.00

Senseonics Holdings, Inc. Common Stock currently has a consensus target price of $17.20, suggesting a potential upside of 66.75%. Given Senseonics Holdings, Inc. Common Stock’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Senseonics Holdings, Inc. Common Stock is more favorable than Trinity Biotech.

Profitability

This table compares Senseonics Holdings, Inc. Common Stock and Trinity Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senseonics Holdings, Inc. Common Stock	-225.09%	-165.80%	-80.14%
Trinity Biotech	-70.06%	N/A	-32.13%

Institutional & Insider Ownership

12.4% of Senseonics Holdings, Inc. Common Stock shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 4.7% of Senseonics Holdings, Inc. Common Stock shares are held by insiders. Comparatively, 8.2% of Trinity Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Senseonics Holdings, Inc. Common Stock and Trinity Biotech”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senseonics Holdings, Inc. Common Stock	$48.55 million	8.88	-$69.11 million	($2.23)	-4.63
Trinity Biotech	$43.78 million	0.13	-$37.38 million	($44.26)	-0.16

Trinity Biotech has lower revenue, but higher earnings than Senseonics Holdings, Inc. Common Stock. Senseonics Holdings, Inc. Common Stock is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Senseonics Holdings, Inc. Common Stock has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company’s products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.